We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Diuretics Are Color Blind

James D. Neaton, PhD; Lewis H. Kuller, MD
JAMA. 2005;293(13):1663-1666. doi:10.1001/jama.293.13.1663.
Text Size: A A A
Published online


The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is considered one of the most important recent clinical trials in hypertension. This mega-trial was motivated by (1) the observation that trials of participants with diastolic blood pressure (BP) in the range of 90 to 114 mm Hg did not result in as large a reduction in coronary heart disease (CHD) incidence as the epidemiologic data suggested should be the case; (2) different classes of antihypertensive drugs were thought to have fewer adverse effects (eg, decreased levels of serum potassium, increased levels of blood glucose and blood cholesterol and triglycerides) than diuretics, and these adverse effects might explain the lower than expected effect on CHD of a diuretic-based BP-lowering treatment; and (3) newer agents that had potentially favorable mechanisms of action might provide benefit above and beyond BP control.1,2 The high prevalence of hypertension in the United States3 and the consequent significance of even moderately reducing the incidence of clinical outcomes through an improved understanding of treatment make studies such as ALLHAT a public health imperative.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Acetazolamide affects performance on the Nagel II anomaloscope. Graefes Arch Clin Exp Ophthalmol 1996;234 Suppl 1():S193-7.